220436-05-5Relevant articles and documents
Pyridobenzodiazepines: A novel class of orally active, vasopressin V 2 receptor selective agonists
Failli, Amedeo A.,Shumsky, Jay S.,Steffan, Robert J.,Caggiano, Thomas J.,Williams, David K.,Trybulski, Eugene J.,Ning, Xiaoping,Lock, Yeungwai,Tanikella, Tarak,Hartmann, David,Chan, Peter S.,Park
, p. 954 - 959 (2007/10/03)
Our efforts in seeking low molecular weight agonists of the antidiuretic peptide hormone arginine vasopressin (AVP) have led to the identification of the clinical candidate WAY-151932 (VNA-932). Further exploration of the structural requirements for agonist activity has provided another class of potent, orally active, non-peptidic vasopressin V2 receptor selective agonists exemplified by the 5,11-dihydro-pyrido[2,3-b][1,5]benzodiazepine as a candidate for further development.
TRICYCLIC VASOPRESSIN AGONISTS
-
Page column 46, (2010/02/08)
-
Tricyclic vasopressin agonists
-
, (2008/06/13)
This invention relates to new compounds selected from those of the general formula (I), or a pharmaceutically acceptable salt, ester or prodrug form thereof: wherein D, E and G are N or CH, which serve as vasopressin agonists and are useful in treating disorders such as diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, and the inability to temporarily delay urination and pharmaceutical compositions and methods for same.